Skip to main content
PMC home page
The BMJ logoLink to The BMJ
editorial
. 1994 May 21;308(6940):1311–1312. doi: 10.1136/bmj.308.6940.1311

Risperidone for schizophrenia.

J G Edwards
PMCID: PMC2540264  PMID: 7517246

Full text

PDF
1311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addington D. E., Jones B., Bloom D., Chouinard G., Remington G., Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther. 1993 Sep-Oct;15(5):917–926. [PubMed] [Google Scholar]
  2. Borison R. L., Pathiraja A. P., Diamond B. I., Meibach R. C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992;28(2):213–218. [PubMed] [Google Scholar]
  3. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
  4. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr;85(4):295–305. doi: 10.1111/j.1600-0447.1992.tb01473.x. [DOI] [PubMed] [Google Scholar]
  5. Heinrich K., Klieser E., Lehmann E., Kinzler E., Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jan;18(1):129–137. doi: 10.1016/0278-5846(94)90029-9. [DOI] [PubMed] [Google Scholar]
  6. Høyberg O. J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielsen M., Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395–402. doi: 10.1111/j.1600-0447.1993.tb03480.x. [DOI] [PubMed] [Google Scholar]
  7. Janssen P. A., Niemegeers C. J., Awouters F., Schellekens K. H., Megens A. A., Meert T. F. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988 Feb;244(2):685–693. [PubMed] [Google Scholar]
  8. Kane J. M. Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. Drugs. 1993 Oct;46(4):585–593. doi: 10.2165/00003495-199346040-00002. [DOI] [PubMed] [Google Scholar]
  9. Leysen J. E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J. C., Janssen P. A. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988 Nov;247(2):661–670. [PubMed] [Google Scholar]
  10. Leysen J. E., Janssen P. M., Gommeren W., Wynants J., Pauwels P. J., Janssen P. A. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol. 1992 Mar;41(3):494–508. [PubMed] [Google Scholar]
  11. Livingston M. G. Risperidone. Lancet. 1994 Feb 19;343(8895):457–460. doi: 10.1016/s0140-6736(94)92696-4. [DOI] [PubMed] [Google Scholar]
  12. Megens A. A., Awouters F. H., Schotte A., Meert T. F., Dugovic C., Niemegeers C. J., Leysen J. E. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994 Feb;114(1):9–23. doi: 10.1007/BF02245439. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES